Home World News Switching to Camizestrant While Continuing a CDK4/6 Inhibitor After ESR1 Mutation Detection... World News Switching to Camizestrant While Continuing a CDK4/6 Inhibitor After ESR1 Mutation Detection Prolongs PFS in ER-positive, HER2-negative ABC By Ogkologos - July 9, 2025 921 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the SERENA-6 study Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR Triple Blockade Demonstrates High Response Rates in Metastatic Melanoma October 14, 2020 Lo que deben saber las personas con cáncer de mama y... January 4, 2024 FDA Approves Pembrolizumab for Advanced MSI-H/dMMR Endometrial Carcinoma April 5, 2022 Mom Fights Second Round Of Breast Cancer — Weeks Later, Her... September 13, 2019 Load more HOT NEWS What Is Peripheral Neuropathy and How Can It Be Prevented or... Zolbetuximab plus CAPOX Prolongs Survival in CLDN18.2-positive, HER2-negative, Locally Advanced Unresectable... ΚΑΡΚΙΝΟΣ ΤΟΥ ΠΝΕΥΜΟΝΑ:ΝΕΑ ΜΕΛΕΤΗ, ΝΕΕΣ ΕΛΠΙΔΕΣ 24-Year-Old Woman with Terminal Breast Cancer Dreams of Fairytale Wedding with...
